CHOICE — what influences EGFR‑TKI treatment decisions for Chinese patients with stage IV non‑small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This non‑interventional, cross‑sectional study uses a survey including a discrete choice experiment (DCE) to capture treatment preferences from physicians and patients with experience of first‑line EGFR‑TKI therapy for stage IV NSCLC. Stage 1 focuses on qualitative work and questionnaire development, including identification of key attributes and pilot testing. Stage 2 implements the finalized quantitative survey and analyzes responses to identify which treatment attributes and patient factors drive decision‑making. Data are collected from consenting adult patients and eligible oncology physicians at the designated research site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

The following inclusion criteria must be met in order to be enrolled in the stage 1:

Patient:

* Provide informed consent
* 18 years or older
* Diagnosed with stage IV NSCLC
* Currently receiving or previously received 1L EGFR-TKI treatment
* Without communication barrier
* Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter

Physician:

* Provide informed consent
* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
* Holding the title of associate chief physician or higher

The following inclusion criteria must be met in order to be enrolled in the stage 2:

Patient:

* Provide informed consent
* 18 years or older
* Diagnosed with stage IV NSCLC
* Currently receiving or previously received 1L EGFR-TKI treatment
* Without communication barrier
* Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter

Physician:

* Provide informed consent
* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
* Holding the title of attending physician or higher

Exclusion Criteria:

Not applicable.

Where it's running

• Research Site
  Chengdu, China Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.